Petros Pharmaceuticals, Inc.
https://metuchenpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Petros Pharmaceuticals, Inc.
Petros Pharma Introduces AI As ACNU Option In Research For OTC Switch Of Stendra ED Drug
Petros is first to introduce an OTC switch labeling tool which could be the next obvious step hiding in plain sight – AI, which wasn’t noted in FDA’s ACNU proposal and hasn’t previously been linked to a switch.
US FDA's ACNU Proposed Rule Played Petros Pharma’s Tune To Attempt OTC Switch Of ED Drug
For ED products, “where you have a contraindication for current use of nitrates, this enables you now to leverage technology to help assist the consumer without a physician intermediary to appropriately self-select. Yes, music to our ears, we loved it,” says president Fady Boctor.
‘Critical Step’ For Petros Toward ED Switch Proposal With OTC Label Comprehension Study
Firm reports “significant comprehension” among 480 participants. It also expects DFL technology it’s developing for potential OTC sales of Stendra ED drug could be used for other OTC switch proposals.
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Metuchen Pharmaceuticals LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice